<DOC>
	<DOCNO>NCT01825876</DOCNO>
	<brief_summary>All study participant receive warfarin study drug call evacetrapib . The main purpose study look much warfarin get blood stream long take body get rid warfarin give without evacetrapib . Another purpose evaluate effectiveness warfarin therapy prevent blood clot give evacetrapib measuring time take blood clot compare average international normalize ratio ( INR ) . INR measure time take blood clot compare average . The study last approximately 5 week , include screening .</brief_summary>
	<brief_title>A Study Evacetrapib ( LY2484595 ) Warfarin Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Evacetrapib</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Participants give write informed consent approve Lilly ethical review board ( ERB ) govern site A medical history physical examination consistent healthy individual Male participant use reliable method birth control ( deem investigator ) donate sperm study 3 month follow last dose investigational product Female participant childbearing potential due surgical sterilization ( least 6 week surgical hysterectomy , bilateral oophorectomy , tubal ligation ) confirm medical history , postmenopausal Have body mass index 18 32 kilogram per square meter ( kg/m^2 ) Participants predict cytochrome P450 2C9 ( CYP2C9 ) extensive metabolizers determine genotyping assessment Have abnormality 12lead electrocardiogram ( ECG ) increase risk associate participate study Have abnormal supine blood pressure Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody evidence hepatitis B and/or positive hepatitis B surface antigen Women pregnant lactating Have use intend use overthecounter prescription medication ( include vitamins/mineral supplement , herbal medicine ) 14 day prior enrollment study Have consume grapefruit , cranberry , grapefruit cranberrycontaining product within 7 day prior first dose warfarin Have history presence significant bleeding disorder , hematemesis , melanena , severe recurrent epistaxis , hemoptysis , clinically overt hematuria intracranial hemorrhage , gastrointestinal ulcer hemorrhage Have personal family history coagulation bleed disorder reasonable suspicion vascular malformation , example , cerebral hemorrhage , aneurysm premature stroke ( cerebrovascular accident le 65 year age ) Have history major head trauma ( loss consciousness ) within past year minor head trauma ( without loss consciousness ) within last 3 month prior screen history major surgery within 3 month screen Have plan surgery within 14 day last day dose Have international normalize ratio/prothrombin time ( INR/PT ) , activate partial thromboplastin time ( aPTT ) normal reference range abnormal Protein S antigen and/or Protein C activity screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>